Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by H. Saber
FDA Approval: Siltuximab for the Treatment of Patients With Multicentric Castleman Disease
Clinical Cancer Research
Cancer Research
Oncology
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Siltuximab: A Targeted Therapy for Idiopathic Multicentric Castleman Disease
Immunotherapy
Oncology
Allergy
Immunology
Biologic Agents in the Treatment of Multicentric Castleman Disease
Turkish Thoracic Journal
Pulmonary
Respiratory Medicine
Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials
The Lancet Haematology
Hematology
Clinicopathologic Characteristics of 342 Patients With Multicentric Castleman Disease in Japan
Modern Rheumatology
Medicine
Rheumatology
Multicentric Castleman Disease: An Unusual Breast Lump
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Predictors of Response to Anti-Il6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial Data
British Journal of Haematology
Hematology
FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease
Clinical Cancer Research
Cancer Research
Oncology
Multicentric Castleman' S Disease Manifesting in the Lung: Clinical, Radiographic, and Pathologic Findings and Successful Treatment With Corticosteroid and Cyclophosphamide.
Internal Medicine
Internal Medicine
Medicine
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
